CBT Pharmaceuticals and Strata Oncology have entered into an agreement to drive patient enrollment in CBT’s ongoing Phase 1/2 trial of CBT-101 in cancer patients with c-Met dysregulated malignancies including non-small cell lung cancer.    Under the terms of the agreement, Strata will exclusively refer Met-amplified, Met-mutation and Met-fusion advanced cancer patients identified through the Strata Trial for enrollment consideration into CBT’s clinical development program for CBT-101. ...